Taken together, these results suggested that intranasal boosting with the RBD-HR vaccine induced a Th1-biased cellular immune response characterized by TNF-α and IL-2 secretion, which has significant implications in the prevention of infection and limiting the spread of SARS-CoV-2. The gene discussed is HR; the disease is infection.